Extract Study by Cannamedical about Pain Ease

Extract Study by Cannamedical about Pain Ease - ESCAPE

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00026906

Enrollment

500

Registered

2022-03-11

Start date

2022-05-25

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic pain

Interventions

Group 1: Efficacy and safety of the use of Cannamedical hybrid cannabis extract THC25:CBD25 in clinical practice.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age = 18 years 2. Presence of chronic pain 3. Previous pain therapies have not been successful due to side effects, insufficient dose, due to side effects, drug interactions or pre-existing conditions, allergic reactions 4. No previous therapy with the Cannamedical-Extract 5. Prescription of medicinal cannabis is indicated 6. Patients who—after having been informed by their physician—have signed the consent and privacy policy.

Exclusion criteria

Exclusion criteria: 1. Existing recreational cannabis use in the last 6 months 2. Existing recreational drug use in the last 6 months 3. Presence of schizophrenia, psychosis, or other psychiatric diseases 4. Known allergies to ingredients or carriers. 5. Presence of pregnancy and lactation and women who are planning to become pregnant during 6. Simultaneous participation in another study 7. Patients who are not capable of giving consent 8. Imprisoned or under-age patients 9. Persons who do not speak German

Design outcomes

Primary

Measure	Time frame
Effect of Cannamedical® Hybrid cannabis extract on average pain intensity measured by 11-item Numerical Rating Scale (NRS). The NRS values of V1 (baseline study) are compared with those of the subsequent visits (V2-V4).	—

Secondary

Measure	Time frame
1. Quality of life, measured by the BPI-SF (general activity, mood, ability to walk, normal work, relationship with others, sleep, enjoyment of life) 2. Quality of life, measured by the SF-12 (vitality, social contacts, emotions in coping with everyday life, well-being). 3. Agility, self-care, general activities, measured by the EQ-5D-3L 4. Duration and quality of sleep, measured by means of the MOS-SS 5. Physician satisfaction with therapy 6. Patient satisfaction with therapy 7. Number of sick days so far	—

Measure

Time frame

1. Quality of life, measured by the BPI-SF (general activity, mood, ability to walk, normal work, relationship with others, sleep, enjoyment of life) 2. Quality of life, measured by the SF-12 (vitality, social contacts, emotions in coping with everyday life, well-being). 3. Agility, self-care, general activities, measured by the EQ-5D-3L 4. Duration and quality of sleep, measured by means of the MOS-SS 5. Physician satisfaction with therapy 6. Patient satisfaction with therapy 7. Number of sick days so far

—

Countries

Germany

Contacts

Public ContactKristina Probst

Cannamedical Pharma GmbH

escape@cannamedical.de+49 (0) 221 999 961 60

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026